Altamira Therapeutics (FRA:2QA) Other Financing: €3.87 Mil (TTM As of Jun. 2025)


FRA:2QA Altamira Therapeutics Ltd FRA:2QA
30 GF Score
Price €948.00
! 4 Warning Signs
View Full Analysis

What is Altamira Therapeutics Other Financing?

Altamira Therapeutics FRA:2QA 30 Other Financing is €3.87 Mil as of Jun. 2025. GuruFocus rates FRA:2QA with a GF Score™ of 30/100. The stock has 4 warning signs investors should review.

Altamira Therapeutics's Other Financing for the six months ended in Jun. 2025 was €-0.01 Mil.

Altamira Therapeutics's Other Financing for the trailing twelve months (TTM) ended in Jun. 2025 was €3.87 Mil.

Altamira Therapeutics Other Financing Historical Data

* Premium members only.

The historical data trend for Altamira Therapeutics's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Altamira Therapeutics Other Financing Chart

Altamira Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.52 6.47 3.86 9.77 6.34

Altamira Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.17 4.41 -0.05 3.87 -0.01
FRA:2QA
30GF Score
Altamira Therapeutics Ltd FRA:2QA
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Altamira Therapeutics Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €3.87 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €3.87 Mil mean?
Altamira Therapeutics (FRA:2QA) has a Other Financing of €3.87 Mil as of Jun. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Altamira Therapeutics and its competitors.
Is Altamira Therapeutics' Other Financing too high?
Altamira Therapeutics' current Other Financing is €3.87 Mil. Overall, Altamira Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Altamira Therapeutics' Other Financing compare to IOBTQ and SCPX?
Altamira Therapeutics' Other Financing of €3.87 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Altamira Therapeutics and its competitors. Altamira Therapeutics's current Other Financing is €3.87 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Altamira Therapeutics stock overvalued right now?
Altamira Therapeutics (FRA:2QA) has a current Other Financing of €3.87 Mil. The current Other Financing is €3.87 Mil. Altamira Therapeutics' overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Altamira Therapeutics (FRA:2QA), the current Other Financing is €3.87 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Altamira Therapeutics Business Description

Other Exchanges CYTOF:USA
Address 2 Church Street, Clarendon House, Hamilton, BMU, HM11
Altamira Therapeutics Ltd is developing and supplying peptide-based nanoparticles for safe and effective RNA delivery to extrahepatic tissues (xPhore platform). The Company is offering biopharmaceutical companies access to its technology for use with their own RNA molecules under collaboration and licensing agreements. The xPhore platform is suitable for various RNA modalities - OligoPhore for oligonucleotides, SemaPhore for mRNA, CycloPhore for circRNA - as well as for DNA (GenePhore). In addition, Altamira Therapeutics is pursuing two proprietary flagship development programs using OligoPhore: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. Geographically, the companies operates in United Staes and Switzerland.
30GF Score

Get the complete analysis for FRA:2QA

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€948.00
Price